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Abstract 
Background: Parkinson disease (PD) is a movement disorder affecting 1 % of people over the age of 60. The etiology 
of the disease is unknown; however, accumulating evidence suggests that mitochondrial defects, oxidative stress, 
and neuroinflammation play important roles in developing the disease. Current medications for PD can only improve 
its symptoms, but are unable to halt its progressive nature. Although many therapeutic approaches are available, 
new drugs are urgently needed for the treatment of PD. Thus, the present study was undertaken to investigate the 
neuroprotective potential of nerolidol, a sesquiterpene alcohol, on a rotenone-induced experimental model of PD, 
where male Wistar rats intraperitoneally received rotenone (ROT) at a dose of 2.5 mg/kg of body weight once daily for 
4 weeks.
Results: Nerolidol, which has antioxidant and anti-inflammatory properties, was injected intraperitoneally at 50 mg/
kg of body weight, once daily for 4 weeks, and at 30 min prior to ROT administration. ROT administration significantly 
reduced the activities of antioxidant enzymes superoxide dismutase (SOD) and catalase (CAT), and the level of the 
antioxidant tripeptide glutathione (GSH). Moreover, ROT increased the levels of the lipid peroxidation product malon-
dialdehyde (MDA), proinflammatory cytokines (IL-1β, IL-6, and TNF-α), and inflammatory mediators (COX-2 and iNOS) 
in rat brain tissues. Immunostaining of brain tissue sections revealed a significant increase in the number of activated 
astrocytes (GFAP) and microglia (Iba-1), along with the concomitant loss of dopamine (DA) neurons in the substantia 
nigra pars compacta and dopaminergic nerve fibers in the striatum of ROT-treated rats. As expected, nerolidol sup-
plementation to ROT-injected rats significantly increased the level of SOD, CAT, and GSH, and decreased the level of 
MDA. Nerolidol also inhibited the release of proinflammatory cytokines and inflammatory mediators. Finally, nerolidol 
treatment prevented ROT-induced glial cell activation and the loss of dopaminergic neurons and nerve fibers, and 
ultimately attenuated ROT-induced dopaminergic neurodegeneration.
Conclusion: Our findings are the first to show that the neuroprotective effect of nerolidol is mediated through its 
anti-oxidant and anti-inflammatory activities, which strongly supports its therapeutic potential for the treatment of 
PD.
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Background
Parkinson disease is a neurodegenerative disorder that 
is characterized by a progressive loss of dopamine (DA) 
neurons in the substantia nigra pars compacta (SNc) 
and dopaminergic nerve terminal fibers of the striatum 
that are enriched in the DA transporter [1]. As a result 
of dopaminergic neurodegeneration, the level of the DA 
neurotransmitter (which mediates the control of move-
ment) is significantly reduced in the striatum. Therefore, 
dopaminergic neurodegeneration leads to impairments 
in movement, a resting tremor, rigidity, and a disturbance 
in gait. Although the etiology for dopaminergic neuronal 
degeneration in PD is not completely understood, cur-
rent evidence suggests that oxidative stress and neuroin-
flammation play key roles in the pathogenesis of PD [2, 
3].
Rotenone (ROT), an inhibitor of mitochondrial com-
plex I, has been widely used as a herbicide/pesticide in 
agriculture. A ROT challenge, due to its complex I inhibi-
tory property, induces pathological features in animals 
that are similar to those seen in human PD patients. 
Thus, ROT-treated animals represent a promising ani-
mal model with construct validity [4–6]. The ROT model 
recapitulates most of the pathological features observed 
in human PD pathogenesis, including the loss of DA neu-
rons in SNc, and enhanced oxidative stress and neuroin-
flammation in the nigrostriatal dopaminergic pathway [2, 
6–8]. Moreover, a ROT challenge to rodents induced the 
formation of α-synuclein cytoplasmic inclusions in DA 
neurons, Lewy pathology, DJ-1 acidification and trans-
location, proteasomal dysfunction, and nigral iron accu-
mulation [9]. Therefore, the ROT-treated rat is a suitable 
model for investigating novel therapeutic agents target-
ing oxidative stress and neuroinflammation in PD.
Currently available drugs alleviate the symptoms of 
PD, but are inadequate in terms of halting the progres-
sion of the disease. Additionally, motor complications 
during advanced stages of the disease, the adverse effects 
of the available drugs, and non-motor symptoms remain 
huge challenges for long-term therapy. Therefore, newer 
therapeutic agents and approaches are urgently needed 
to stop or delay the progressive nature of the disease [10]. 
PD is intimately connected to excessive oxidative stress 
that damages brain areas and accelerates the process of 
neurodegeneration, especially in the nigrostriatal area. 
This process is an important breakpoint for controlling 
the disease. Consequently, in addition to other therapeu-
tic approaches, treatment with antioxidants is gradually 
gaining importance in the pharmacotherapy of PD.
Plants are a potential source of novel drugs to benefit 
mankind. Much research effort has focused on discover-
ing new antioxidant compounds from plants. An increas-
ing number of studies have shown that essential oils 
obtained from medicinal plants exhibit a variety of bio-
logical properties, such as anticonvulsant [11], analgesic 
[12], anxiolytic [13], antidepressant [14], antioxidant [15], 
and anti-inflammatory [16] properties. Some of these 
effects are frequently attributed to terpenes, which are 
chemical components that are present in these essential 
oils [11, 17]. Nerolidol (NRD) [3,7,11-trimethyl-1,6,10-
dodecatrien-3-ol] is a sesquiterpene alcohol (Fig.  1) that 
is found in essential oils from plants such as Baccharis 
dracunculifolia [18], Amaranthus retroflexus [19], and 
Canarium schweinfurthii [20]. Nerolidol is an aliphatic 
sesquiterpene that is commonly used in cosmetics, per-
fumes, shampoos, and soaps [21], as well as non-cosmetic 
products (cleansers and detergents). Essential oils from 
Ferula fukanensis containing nerolidol have been shown 
to prevent nitric oxide (NO) production and NO-induced 
gene expression, suggesting its plausible use as an antioxi-
dant agent. NRD is hydrophobic in nature with an XlogP3 
value of 4.6 (>2.5 is needed for efficient transport across 
blood brain barrier), and thus NRD can cross easily the 
blood brain barrier. NRD significantly reduces the level 
of lipid peroxidation and nitrite content in the hippocam-
pus of mice, which protects against oxidative stress [15], 
suggesting an important antioxidant property for NRD. 
A recent study reported that NRD reduces interleukin-1β 
(IL-1β) production in lipopolysaccharide-induced perito-
neal macrophages [16]. Additionally, NRD shows potent 
anti-inflammatory activity through the suppression of 
IL-1β and tumor necrosis factor-alpha (TNF-α) levels in 
an experimental mouse model of pain [16]. Therefore, the 
main objective of the present study was to investigate the 
anti-oxidative and anti-inflammatory effects of NRD on 
ROT-induced neurodegeneration in rats.
Methods
Drugs and chemicals
Polyclonal rabbit anti-cyclooxygenase-2 (COX-2), anti-
inducible nitric oxide synthase (iNOS), and anti-glial 
fibrillary acidic protein (GFAP) antibodies were pur-
chased from Abcam, Cambridge, MA, USA. Anti-ionized 
calcium-binding adaptor molecule-1 (Iba-1) polyclonal 
rabbit antibody was procured from Wako Chemicals, 
Richmond, VA, USA. Polyclonal rabbit anti-tyrosine 
hydroxylase antibody was obtained from Novus Biologi-
cals, Littleton, CO, USA. Alexa fluor 488 conjugated sec-
ondary goat anti-rabbit antibodies were purchased from 
Life Technologies, Grand Island, NY, USA. Biotinylated 
secondary anti-rabbit antibody was purchased from 
Jackson Immunoresearch, West Grove, PA, USA. Nero-
lidol was purchased from Santa Cruz Biotechnology Inc., 
CA, USA. ROT and the assay kit for reduced glutathione 
(GSH) and other reagents of analytical grade were pur-
chased from Sigma-Aldrich, St. Louis, MO, USA.
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Experimental animals
We used male Wistar rats at 6–7 months old (weighing 
280–300 g) from the Animal Research Facility of the Col-
lege of Medicine and Health Sciences, United Arab Emir-
ates University, UAE. Prior to the start of the experiment, 
a maximum of 4 rats were housed per cage, and rats were 
acclimatized for 1 week to the laboratory conditions. The 
cages of the animals were changed twice a week. The 
animals were housed and kept under standard labora-
tory light and dark cycle conditions. The animals were 
fed with commercially available rodent food and water 
ad  libitum. All experiments were conducted between 
0900 and 1500  hours. The Animal Ethics Committee of 
the United Arab Emirates University, UAE, approved the 
experimental protocol for animal experimentation.
Experimental design
To induce the PD in rats, ROT (2.5 mg/kg body weight) was 
administered intraperitoneally (i.p.) once daily for 4 weeks. 
The regimen used in the current study for the induction 
of Parkinsonism in rats was adopted as reported earlier 
[22]. Briefly, ROT was first dissolved in dimethyl sulfox-
ide (DMSO) to prepare a 50X stock solution and stored 
at −80 °C for further use. Before injection, the stock solu-
tion of ROT was thawed and further diluted in sunflower 
oil to obtain a final concentration of 2.5 mg/mL. To evalu-
ate its neuroprotective efficacy, NRD was initially diluted in 
olive oil to obtain a final concentration of 50 mg/2 mL, and 
injected i.p. 30 min prior to ROT administration at a dose 
of 50  mg/kg of body weight once daily for 4  weeks. The 
dose of NRD was selected based on dose–response stud-
ies (data not shown) as well as earlier reports [15, 23]. Rats 
that were used as controls received an equivalent volume of 
vehicle only. The animals were sacrificed 48 h after the last 
injection of NRD or ROT or both in combination to com-
pletely eliminate these drugs from the body. The rats were 
divided into 4 experimental groups where each group con-
sisted of 8 animals; the groups were named as follows:
Group I, the vehicle-injected control group (CONT).
Group II, the rotenone-injected and vehicle-treated 
group (ROT).
Group III, the rotenone-injected and NRD-treated 
group (ROT + NRD).
Group IV, the NRD-only injected group (NRD).
Tissue collection
At the end of the experiment, the animals from all groups 
were anaesthetized with pentobarbital (40 mg/kg of body 
weight) and a cardiac perfusion was performed using 
0.01  M of phosphate-buffered saline (PBS) pH 7.4 to 
completely clear the blood. The skull of the rat was open 
to quickly isolate the brain. The brain was placed on an 
ice-plate and cut along the midline to separate the 2 cer-
ebral hemispheres. For biochemical assay, the midbrain 
and striatum regions of the brain were isolated from 1 
hemisphere and immediately fresh frozen in liquid nitro-
gen for further use. The other hemisphere of the brain 
was incubated in 4 % paraformaldehyde solution for 48 h 
and subsequently exchanged with 10 % sucrose solution 
containing 0.1 M of phosphate buffer (PB) 3 times daily 
for 3 consecutive days at 4 °C prior to cryostat sectioning.
Sample preparation for biochemical assay
For biochemical assay, the midbrain tissue of each ani-
mal was homogenized in KCl buffer (10-mM Tris–HCl, 
140-mM-NaCl, 300-mM KCl, 1-mM EDTA, and 0.5  % 
Triton X-100) at pH 8.0 supplemented with protease 
and phosphatase inhibitor, keeping the samples on ice. 
The tissue homogenates of each sample were centrifuged 
at 14,000×g for 20 min at 4  °C to obtain the post-mito-
chondrial supernatant (PMS) fraction. This PMS fraction 
was used to estimate the levels of the antioxidant enzyme 
GSH, lipid peroxidation product, and proinflammatory 
cytokines using spectrophotometric measurements and 
an enzyme-linked immunosorbent assay (ELISA) follow-
ing a standard protocol, as reported earlier [22].
Assay for lipid peroxidation
A malondialdehyde (MDA) assay kit procured from 
Northwest Life Science (Vancouver, WA, USA) was 
used to determine the amount of lipid peroxidation, as 
reported earlier [22]. Briefly, the samples or standards 
(250 µL) were incubated in the presence of acid reagent 
(250  µL) and thiobarbituric acid (250  µL) and vortexed 
vigorously. Samples were further incubated for 60 min at 
60 °C followed by centrifugation at 10,000×g for 2–3 min. 
The reaction mixture was then aseptically transferred 
without disturbing the pellet to a cuvette and the absorb-
ance was recorded at 532 nm. The concentration of MDA 
was calculated using a standard curve and expressed as 
µM MDA/mg protein.
Estimation of GSH
A GSH kit was used to estimate the GSH level, as reported 
earlier [22]. Briefly, the samples were first deproteinized 
with 5  % 5-sulfosalicylic acid solution and centrifuged 
to remove the precipitated protein. The supernatant was 
used to measure the GSH level. Samples and standards 
Fig. 1 Chemical structure of nerolidol
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of different concentrations (10  µL) were added in each 
well of a 96-well plate and incubated for 5 min with the 
working mixture (150  µL; assay buffer  +  5,5′-dithiobis 
(2-nitrobenzoic acid)  +  glutathione reductase). Diluted 
NADPH solution (50  µL) was added to each well and 
mixed properly. The absorbance of the samples was 
measured at 412  nm with kinetics capability for 5  min 
using a microplate reader. The results were expressed as 
µM GSH/mg protein.
Assay for antioxidant enzymes activity
The activity of antioxidant enzymes such as superoxide 
dismutase (SOD) and catalase (CAT) were determined 
following the manufacturer’s instructions of a kit (Cay-
man Chemicals Company, Ann Arbor, MI, USA), as 
reported earlier [22]. The CAT activity was expressed 
as nmol/min/mg protein and the SOD activity was 
expressed as U/mg protein.
Assay for pro‑inflammatory cytokines
Commercially available ELISA kits for IL-1β, IL-6, and 
TNF-α were purchased from R&D systems, Minneapo-
lis, MN, USA. The level of IL-1β, IL-6, and TNF-α were 
estimated as described earlier [22]. The results were 
expressed as pg/mg protein.
Immunohistochemistry for tyrosine hydroxylase (TH) 
expression
The one hemisphere of the brains collected from each 
animal were serially cut after fixation and processed for 
immunohistochemical analysis. Briefly, 14 μm-thick cor-
onal brain sections were cut at the level of the striatum 
and SNc using a cryostat (Leica, Wetzlar, Germany) for 
the immunohistochemical analysis of TH. Sections were 
washed twice with 0.01 M of PBS, pH 7.4, and then incu-
bated with blocking reagent (10 % normal goat serum in 
PBS containing 0.3 % Triton-X 100) for 1 h. Next, the sec-
tions were incubated overnight with a primary polyclonal 
rabbit antibody against TH (1:500) at 4 °C. Sections were 
washed and incubated with biotinylated secondary anti-
rabbit (1:1000) antibody for 1  h at room temperature. 
The brain sections were incubated with avidin–biotin 
complex (Vector Laboratories Ltd. Burlingame, CA, 
USA) and 3,3′ diaminobenzidine (DAB) to visualize and 
analyze the TH immunoreactivity. Finally, the sections 
were coverslipped using DPX mounting medium. The 
slides were then viewed under a light microscope (Olym-
pus, Hamburg, Germany) and images were acquired for 
analysis.
Immunofluorescence staining of GFAP and Iba‑1
Immunofluorescence staining was performed using 
14  µm-thick striatum sections to quantify the number 
of activated GFAP-positive astrocytes and Iba-1-positive 
microglia. The brain sections were first washed twice 
with PBS and incubated with blocking reagent (10 % nor-
mal goat serum in PBS containing 0.3 % Triton-X 100) for 
1 h. The sections were then incubated overnight with the 
primary polyclonal rabbit antibodies ant-GFAP (1:1000) 
and anti-Iba-1 (1:1000) at 4 °C. The sections were washed 
and incubated with fluorescent secondary anti-rabbit 
Alexa fluor 488 antibody for 1  h at room temperature. 
Sections were then washed, mounted on slides, and 
coverslipped using the mounting medium Fluoroshield 
(Sigma Aldrich, St. Louis, MO, USA). The images were 
captured using a fluorescence microscope EVOS FL 
(Thermo Fisher Scientific, Waltham, MA, USA).
Assessment of TH‑immunopositive (TH+) dopamine (DA) 
neurons in the SNc and TH‑immunoreactive (TH‑ir) DA 
nerve fibers in the striatum
To evaluate the ROT-induced neurodegeneration and 
neuroprotective effect of NRD, the total number of 
TH+ DA neurons at 3 different anatomical levels of the 
SNc (−4.8, −5.04, and −5.28 mm of the bregma) were 
counted. The average number of TH+ neurons were 
calculated and converted as a percentage with reference 
to the control. The loss of striatal fibers was evaluated 
by measuring the intensity of TH-ir dopaminergic fibers 
in the striatum using Image J software (NIH, Bethesda, 
MD, USA). The intensity of the TH-immunoreactive 
nerve fibers in 3 different fields of brain sections (3 sec-
tions per animal) within the striatal region (adjacent to 
0.3  mm of the bregma) was measured to examine the 
DA nerve fibers loss. An average of the 3 sections was 
calculated and presented as a percentage with refer-
ence to the values of the control group. The intensity of 
the overlying cortex area was used as the background 
measurement and subtracted from the value generated 
from the striatum. An investigator that was ‘blind’ to the 
experimental groups counted the TH+ DA neurons and 
determined the immunoreaction intensity of the TH 
fibers.
Assessment of activated astrocytes and microglia in the 
striatum
Three coronal sections from a comparable anatomical 
level of striatum from each animal were used to analyze 
and count the number of activated astrocytes and micro-
glia. Activated astrocytes and microglia were considered 
for counting based on the intense immunoreactivity of 
GFAP- and Iba-1-labeled cells, whose characteristic mor-
phological features include hypertrophied and extended 
glial processes. The total number of activated astrocytes 
and microglia were counted from 3 randomly chosen 
fields of an equal area in each section using the Image 
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J software (NIH, Bethesda, MD, USA), and the results 
were presented as a percentage.
Western blot analysis of COX‑2 and iNOS expression
Western blot analysis was carried out to measure the 
level of COX-2 and iNOS expression in different groups 
of animals following the protocol, as reported earlier 
[22]. Briefly, striatal tissues isolated from each animal 
were homogenized in radioimmuno-precipitation buffer 
with protease and phosphatase inhibitors. The cell lysates 
were then centrifuged at 15,000  rpm for 20  min. The 
supernatant containing cytoplasmic fractions was iso-
lated, and protein concentration was measured as men-
tioned below. The cytoplasmic fraction containing equal 
amounts of protein (35  μg) were loaded and separated 
using 10 % SDS–polyacrylamide gel electrophoresis. The 
proteins were then transferred onto a PVDF membrane 
and incubated overnight at 4  °C with specific primary 
rabbit polyclonal antibodies against COX-2 (1:1000) and 
iNOS (1:500). The membrane was washed and then incu-
bated with horseradish peroxidase-conjugated secondary 
anti-rabbit antibody. The protein recognized by the anti-
body was visualized using an enhanced chemilumines-
cence Pico kit (Thermo Fisher Scientific, Rockford, IL, 
USA). The blots were stripped and re-probed for β-actin 
(1:5000; monoclonal mouse, Millipore, MA, USA) as a 
loading control. The intensity of the bands was measured 
using densitometry and quantified using Image J software 
(NIH, Bethesda, USA).
Protein estimation
The concentration of protein in each sample was esti-
mated using the Pierce BCA protein assay kit (Thermo 
Fisher Scientific, Rockford, IL, USA) following the manu-
facturer’s instructions.
Statistical analyses
The data were expressed as the mean value ± SEM. The 
data were analyzed with Graph Pad (InStat software, 
La Jolla, CA, USA) using a one-way analysis of variance 
(ANOVA) followed by a Tukey’s test to determine the 
statistical significance between various groups. For all of 
the tests, the criterion for any statistically significant dif-
ference was set at p < 0.05.
Results
NRD administration prevents the loss of DA neurons in the 
SNc and DA nerve fibers in the striatum
To investigate the beneficial effect of NRD on DA neu-
rodegeneration in ROT-injected rats, TH immunohisto-
chemical analysis was performed to assess the expression 
of healthy TH+ DA neurons in the SNc and the TH-ir 
DA nerve fibers density in the striatum. The results show 
that chronic ROT treatment caused a significant loss 
(p  <  0.05) of DA neurons in the SNc area as expected 
when compared to vehicle-injected control rats (Fig. 2a, 
c). In contrast, NRD supplementation prior to ROT 
injection in rats provided significant (p < 0.05) protection 
to DA neurons when compared to only ROT injection 
of rats. The DA neurons of the SNc project their nerve 
terminals to the striatum where they are highly enriched 
with the dopamine transporter (DAT). Degeneration 
of DA neurons in the SNc decreases DAT expression in 
the striatum, which further confirms the neuronal loss. 
Therefore, we examined whether the loss of DA neu-
rons in the SNc area is correlated with DA-terminal loss 
by measuring the intensity of TH-ir dopaminergic nerve 
terminal fibers of the striatum. A significant decrease 
(p < 0.05) was observed in the intensity of TH-ir fibers in 
ROT-injected animals when compared to vehicle-treated 
controls. However, NRD supplementation prior to ROT 
administration significantly increased (p  <  0.05) TH-ir 
intensity in nerve terminal fibers, suggesting that NRD 
has a potent neuroprotective effect against ROT-induced 
dopaminergic neurodegeneration (Fig. 2b, d).
NRD treatment suppresses excessive lipid peroxidation 
and ameliorates GSH levels
Next, we tested whether NRD mediated the neuropro-
tective effect that we observed in our model is due to 
its antioxidant activity because NRD is an antioxidant. 
To clarify this issue, the role of NRD in ROT-induced 
neurodegeneration was investigated by examining the 
level of MDA, a marker for lipid peroxidation in the 
midbrain region. As shown in Fig.  3a, ROT treatment 
resulted in a massive amount of MDA production in the 
ROT group of animals when compared to control rats. 
Treatment with NRD significantly abolished (p  <  0.05) 
the elevated MDA production. Increased MDA produc-
tion due to oxidative stress correlated with a decrease in 
the bioavailability of the tripeptide antioxidant GSH in 
midbrain cells. The ROT-challenged rats also showed a 
significantly decreased (p < 0.05) level of GSH compared 
to vehicle-injected control rats (Fig.  3b). Supplementa-
tion with NRD prior to ROT administration significantly 
attenuated (p < 0.05) the level of GSH compared to the 
ROT-injected rats. Taken together, these results suggest 
that the neuroprotective effect of NRD on ROT-induced 
neurodegeneration might be mediated through its anti-
oxidative effect.
NRD reverses the ROT‑induced decrease in the activity 
of antioxidant enzymes
We also measured the activity of antioxidant enzymes 
SOD and CAT. ROT administration significantly 
decreased (p  <  0.01) SOD and CAT activity when 
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compared with the vehicle-injected control group. How-
ever, NRD supplementation significantly increased 
(p < 0.05) the activities of SOD (Fig. 3c) and CAT (Fig. 3d) 
when compared with the ROT-injected animals. Control 
animals did not show any significant changes in the activ-
ities of SOD and CAT when compared to the NRD-only-
injected rats.
Neuroprotective effects of NRD involves the inhibition 
of glial cell activation
Glial cell (astrocyte and microglia) activation follow-
ing ROT administration has been observed, and is con-
sidered to be an index of the inflammatory response. 
We observed an increase in the expression of GFAP 
and Iba-1, which are markers of activated astrocytes 
and microglia, respectively, upon ROT administration. 
Immunofluorescence staining showed a significant 
increase (p < 0.01) in the number of activated astrocytes 
and microglia in ROT-injected animals compared to 
the vehicle-injected control animals (Fig.  4a–d). Inter-
estingly, NRD treatment to the ROT-injected rats sig-
nificantly decreased (p  <  0.05) the number of activated 
astrocytes and microglia compared to the ROT-injected 
rats. Animals injected with NRD alone did not show any 
remarkable activation of astrocytes and microglia when 
compared to control animals.
NRD attenuates the ROT‑induced release 
of proinflammatory cytokines
The persistent activation of astrocytes and microglia 
accompanied by the sustained secretion of inflamma-
tory mediators is thought to be involved in the neuronal 
Fig. 2 Expression of tyrosine hydroxylase (TH)-immunopositive (TH+) dopamine (DA) neurons in the substantia nigra pars compacta (SNc) and 
TH-immunoreactive (TH-ir) dopaminergic nerve fibers in the striatum. The scale bar is 100 µm. a The number of TH+ neurons was decreased in the 
SNc region of the rotenone (ROT)-injected rats compared to the control (CONT) group. In contrast, nerolidol (NRD) administration rescued the TH+ 
neurons in the ROT + NRD injected rats compared to the ROT rats. b The expression of TH-ir fibers in the striatum of the CONT, ROT, ROT + NRD, 
and NRD-only group of rats. c The number of TH+ positive DA neurons in the SNc was counted from each group. A significant decrease (*p < 0.05) 
in the number of DA neurons was observed in the SNc of the ROT group compared to the CONT group. NRD treatment significantly (#p < 0.05) pro-
tected the DA neurons from the ROT-induced neuronal death. No significant difference was observed in the DA neurons of the CONT and NRD-only 
group. Values are expressed as percent mean ± SEM (n = 3). d A significant decrease (*p < 0.05) in the TH-ir fibers was observed in the ROT group 
compared to the CONT group. NRD treatment significantly inhibited (#p < 0.05) the loss of TH-ir fibers in the ROT + NRD group compared to the 
ROT group. The CONT rats and NRD-only-injected rats did not show a remarkable loss of TH-ir fibers
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injury in PD. Therefore, the release of proinflammatory 
cytokines such as IL-1β, IL-6, and TNF-α in response 
to ROT exposure was examined and quantified using 
ELISA. A significant increase (p  <  0.01) in the IL-1β, 
IL-6, and TNF-α level was observed in the ROT-injected 
animals when compared to the vehicle-injected control 
animals (Fig.  5a–c). However, NRD supplementation to 
the ROT-administered animals significantly decreased 
(p  <  0.05) the level of these proinflammatory cytokines 
when compared to the ROT-injected animals (Fig. 5a–c). 
Animals injected with NRD alone did not show any sig-
nificant changes in the level of analyzed proinflammatory 
cytokines when compared to control animals.
Effect of NRD on the expression of COX‑2 and iNOS
The expressions of COX-2 and iNOS were also exam-
ined using Western blot in tissue lysates that were iso-
lated from the striatum region (Fig. 6a, b). A significant 
increase (p  <  0.05) in COX-2 expression (Fig.  6c) was 
observed in ROT-treated animals (217.42 vs. 100  %) 
when compared to the vehicle-injected control group 
of animals. However, following treatment with NRD in 
the ROT-administered rats, a remarkable reduction in 
the level of COX-2 (148.16 vs. 217.42  %) was observed 
when compared to the ROT-treated rats. ROT adminis-
tered animals also showed a significant increase (p < 0.05, 
206.35 vs. 100 %) in iNOS expression (Fig. 6d) when com-
pared to the control animals. Interestingly, NRD supple-
mentation to the ROT-injected rats modestly decreased 
(156.16 vs. 206.35  %) iNOS induction when compared 
to the ROT-treated rats. Treatment with only NRD 
decreased COX-2 expression by 10.1 % (89.9 vs. 100 %), 
whereas a slight increase of 2.76 % (102.76 vs. 100 %) in 
iNOS expression was observed when compared to the 
control group.
Discussion
PD is one of the most common progressive neurodegen-
erative disorders with a complex pathogenesis. The cur-
rent hypothesis suggests that mitochondrial dysfunction, 
oxidative stress, and neuroinflammation play a crucial 
role in the development of PD. Systemic administration 
of ROT to rats has been shown to induce behavioral and 
pathological symptoms of PD, such as motor dysfunction, 
Fig. 3 Quantification of malondialdehyde (MDA), glutathione (GSH), superoxide dismutase (SOD) and catalase (CAT) in midbrain tissue. Rotenone 
(ROT) exposure induced a significant increase (**p < 0.01) in the MDA level (a) and a decrease in the GSH level (b) in the midbrain of the ROT-
challenged rats compared to the vehicle injected control (CONT) rats. NRD supplementation to the ROT-administered rats significantly decreased 
(#p < 0.05) the level of MDA, and increased (##p < 0.01) the level of GSH. ROT injection also significantly decreased (**p < 0.01) the activity of SOD (c) 
and CAT (d) compared to the CONT rats. NRD supplementation significantly inhibited (#p < 0.05) the ROT-induced decrease in SOD and CAT activity 
compared to the ROT-injected rats. Values are expressed as the mean ± SEM (n = 6–8)
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dopaminergic neurodegeneration, oxidative stress, 
inflammation, and α-synucleinopathy [6, 22, 24, 25]. In 
the present study, the ROT-induced PD model was used 
to investigate the neuroprotective potential of the NRD 
phytochemical, which recently showed potential antiox-
idant activity [15]. ROT at a dose of 2.5  mg/kg of body 
weight once daily was used for 4 weeks to induce dopa-
minergic neurodegeneration. Our results show the novel 
potential benefits of NRD in attenuating dopaminergic 
neurodegeneration, improving antioxidant enzymes, and 
inhibiting inflammatory mediators and lipid peroxidation 
in the brain.
Tyrosine hydroxylase (TH) is a rate-limiting enzyme 
that catalyzes the synthesis of the DA neurotransmit-
ter, which is synthesized in the dopaminergic neurons 
of the SNc area. DA is stored in synaptic vesicles and, in 
response to stimuli, released in the striatum to exert its 
physiological function [26]. In PD patients, more than 
70 % of the dopaminergic neurons are dead resulting in 
the retraction of dopaminergic nerve terminals in the 
striatum and depletion of DA in the striatum [27]. There-
fore, the death of dopaminergic neurons in the SNc is 
believed to decrease the level of striatal dopamine. The 
loss of dopaminergic neurons in the SNc and reduced 
density of striatal nerve terminals are considered to be 
the pathological hallmark of human PD [28].
In the present study, immunohistochemical examina-
tion of TH revealed that ROT causes a significant loss of 
TH+ dopaminergic neurons in the SNc area and the den-
sity of dopaminergic nerve terminal fibers in the striatum, 
which concurs with previous reports [22, 25]. Interestingly, 
NRD supplementation to ROT-treated rats significantly 
protected against the ROT-induced loss of dopaminergic 
neurons in the SNc and reduced striatal nerve fiber density 
in the striatum. This result indicates that NRD has neuro-
protective effects that prevent dopaminergic neuron loss 
Fig. 4 Striatal glial fibrillary acidic protein (GFAP)-positive astrocytes and ionized calcium binding adaptor molecule-1 (Iba-1)-positive microglia. 
Profound expression of GFAP-positive astrocytes (green, a) and Iba-1-positive microglia (green, b) was found in the ROT-administered rats compared 
to the vehicle-injected CONT rats. In contrast, NRD supplementation to the ROT injected rats showed moderate staining of GFAP and Iba-1 com-
pared to the ROT-injected rats (scale bar = 200 µm). Quantitative analysis of activated astrocytes (c) and microglia (d) revealed a significant increase 
(**p < 0.01) in the number of activated astrocytes and microglia in the ROT group rats compared to the CONT group. However, NRD supplemen-
tation significantly reduced (#p < 0.05) the number of activated astrocytes and microglia in the ROT + NRD group compared to the ROT group. 
CONT rats and NRD-only-injected rats did not show any marked difference in the activation of astrocytes and microglia. Values are expressed as the 
percent mean ± SEM (n = 3)
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Fig. 5 Proinflammatory cytokines in the midbrain tissue of the CONT, ROT, ROT + NRD, and NRD-only groups. The level of IL-1β (a), IL-6 (b), and 
TNF-α (c) was significantly increased (**p < 0.01) in the ROT-treated group when compared to the CONT group. However, NRD treatment signifi-
cantly decreased (#p < 0.05) the ROT-induced increase of these proinflammatory cytokines in the ROT + NRD group. No significant differences were 
observed in these cytokines between the CONT and NRD-only group. Values are expressed as the mean ± SEM (n = 6–7)
Fig. 6 Western blot analysis of COX-2 and iNOS expression in striatal tissue. COX-2 (a) and iNOS (b) expression levels were determined using 
Western blotting in the striatum. The ROT-administered group showed significant increase (*p < 0.05, 217.42 vs. 100 %) in the COX-2 level compared 
to the CONT group. NRD supplementation to the ROT-injected rats remarkably decreased the expression level of COX-2 (148.16 vs. 217.42 %) 
compared to the ROT group (c). Likewise, iNOS expression was also significantly increased (*p < 0.05, 206.35 vs. 100 %) in the ROT group compared 
to the CONT group. NRD treatment markedly decreased the iNOS expression (156.16 vs. 206.35 %) compared to the ROT group (d). NRD-only treat-
ment decreased (89.9 vs. 100 %) COX-2 expression, while an increase (102.76 vs. 100 %) in iNOS expression was observed when compared to the 
CONT group (n = 3)
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and striatal nerve terminal retraction in ROT-induced PD 
in rats. A convincing number of studies have shown that 
dopaminergic neurons exist in a state of constant oxida-
tive stress, as brain cells have a low antioxidant defense 
capacity and a tendency to generate reactive oxygen spe-
cies due to the presence of highly oxidizable DA [29, 
30]. In our study, NRD administration protected against 
ROT-induced dopaminergic neurodegeneration possibly 
through its strong antioxidant action, as NRD shows effi-
cient antioxidant activity in the hippocampus [15].
Defects in complex-I of the mitochondrial electron 
transport chain leads to a massive release of free radi-
cals, and consequently, cellular death [31]. ROT, which is 
an inhibitor of complex-I of the mitochondrial electron 
transport chain, upon systemic administration to rats, 
causes the loss of ATP production and subsequently gen-
erates reactive oxygen species [30]. Furthermore, reactive 
oxygen species induce the oxidation of polyunsaturated 
fatty acid in a process called lipid peroxidation, which is 
characterized by the formation of MDA, a major prod-
uct of lipid peroxidation that forms adducts with DNA 
bases and proteins, thereby causing cellular damage. The 
increased level of oxidative damage to DNA, proteins, 
and lipids, and decreased level of antioxidants have been 
reported in the brain of PD patients [4]. Significantly 
increased levels of MDA in the ROT-treated rats were 
observed compared to the vehicle-injected control rats. 
Interestingly, NRD supplementation to the ROT-injected 
rats significantly lowered the levels of MDA compared to 
the ROT-injected rats. Notably, NRD ameliorates against 
oxidative stress due to lipid peroxidation in the mouse 
hippocampus [15]. The inhibition of lipid peroxidation 
by NRD in the current study may have been mediated 
through the detoxification of peroxy radicals and reactive 
oxygen species, which further supports an antioxidative 
role for NRD.
GSH is an important antioxidant and has a crucial role 
in scavenging hydrogen peroxide. The decreased lev-
els of GSH in the brain might indicate a state of oxida-
tive stress. Decreased levels of GSH have been observed 
in surviving dopaminergic neurons of the SNc of PD 
patients compared to age-matched controls [32]. In the 
present study, the GSH level was significantly lower in 
ROT-treated rats than in control rats. Decreased levels 
of GSH lead to oxidative damage to DNA, protein, and 
lipids in PD [32–34]. Administration of NRD significantly 
increased GSH levels compared to the ROT injected and 
vehicle-treated rats (Group II). The effect of NRD on 
GSH may involve the direct antioxidant effects of NRD or 
the prevention of ROT-induced GSH oxidation.
SOD and CAT are the main antioxidant enzymes 
involved in detoxifying free radicals. The loss of SOD 
activity further contributes to an increase in oxidative 
stress in ROT-treated rats. Complex-I of the mitochon-
drial respiratory chain is the major source of superoxide 
radicals through inhibition of the electron transport chain 
[28]. The diminished activity of SOD would be detrimen-
tal in the scenario when superoxide radical production is 
increased. Our present data showed decreased activity of 
SOD in ROT-challenged rats compared to control rats. 
The administration of NRD was beneficial, because this 
treatment efficiently restored the SOD activity in ROT-
injected rats. This result corroborated a previous report 
showing an increase in SOD activity after NRD adminis-
tration [15]. CAT is an enzyme that is responsible for cat-
alyzing the decomposition of H2O2. The maintenance of a 
normal metabolism of reactive oxygen species is impor-
tant for proper cell function in different body parts [35, 
36]. In the present study, CAT activity was significantly 
diminished in ROT-injected rats, while the administration 
of NRD significantly reversed the decreased activity of 
CAT in NRD-supplemented rats. NRD supplementation 
reduced oxidative damage, as observed by the decrease in 
lipid peroxidation, restoration of the GSH level, and activ-
ities of the antioxidant enzymes (SOD and CAT) follow-
ing ROT administration in rats.
Furthermore, ROT-treated animals showed an increase 
in neuroinflammation that is triggered and sustained 
through various mechanisms. Dysfunction of complex-I 
of the mitochondrial respiratory chain due to ROT treat-
ment increased the release of reactive oxygen species, 
which can trigger the activation of glial cells [37]. A large 
number of studies report the involvement of neuroin-
flammation in PD, which is largely characterized by an 
accumulation of activated microglia [38]. The activation 
of astrocytes and microglia results in increased expres-
sion of GFAP and Iba-1, respectively. Microglial activa-
tion also causes NO· overproduction via iNOS induction 
[39]. Robust microgliosis and increased expression of 
iNOS have also been reported in postmortem brain sam-
ples of PD patients [40, 41]. Proinflammatory cytokines 
such as IL-1β, IL-6, and TNF-α, and enzymes such as 
iNOS and COX-2 appear to be involved in DA toxicity, 
and have been observed in the cerebrospinal fluid and 
postmortem brain tissue samples of PD patients [40, 
42–45].
In addition, inflammatory processes that are associ-
ated with the increased expression of COX-2 and iNOS 
are involved in the cascade of deleterious events that 
leads to neurodegeneration in PD [46]. In line with this 
report, here we showed an increase in activated astro-
cytes and microglia with a concomitantly enhanced level 
of the proinflammatory cytokines IL-1β, IL-6, and TNF-α 
in ROT-treated rats, which was significantly attenuated 
following NRD supplementation. Additionally, NRD sup-
plementation normalized the expression of COX-2 and 
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iNOS in the ROT-injected rats. Therefore, the present 
findings further suggest that NRD exerts its anti-inflam-
matory effects through inhibiting the increased level of 
COX-2 and iNOS, as well as proinflammatory cytokines. 
The NRD-mediated suppression of inflammation, as 
observed in the present study, could be facilitated by the 
strong anti-inflammatory activity of NRD that has been 
reported in other studies [47, 48]. NRD has also been 
shown to inhibit the lipopolysaccharide-induced release 
of pro-inflammatory cytokines in bone marrow-derived 
dendritic cells, and diminish the induction of inflamma-
tory mediators in an in  vivo acute model of inflamma-
tion [49, 50]. Oxidative stress and neuroinflammation 
play major roles in different neurodegenerative diseases 
such as stroke, Alzheimer’s disease, and PD [51]. Drugs 
with anti-oxidative and anti-inflammatory characteris-
tics are considered effective therapeutic agents for these 
neurodegenerative diseases [52]. Therefore, NRD, with its 
effective antioxidant and anti-inflammatory properties, 
may be responsible for the neuroprotection in the ROT-
induced rat model of PD.
Conclusions
In conclusion, our study suggests that NRD supple-
mentation ameliorates the ROT-induced dopaminergic 
neurodegeneration through its antioxidant and anti-
inflammatory activities. The present results highlight the 
therapeutic potential of NRD in neurodegenerative dis-
eases including PD. However, further study is required to 
fully understand the molecular mechanisms of how NRD 
potentiates antioxidant and anti-inflammatory activities.
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